Emergency departments are unique to describe antithrombotic-related major haemorrhage. 23
We report the results of a prospective cohort that aimed to describe antithrombotic-related 24 major haemorrhage, diagnostic process, clinical and therapeutic management as well as 1-25 month outcome .  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  Material and methods  1  2  Patient selection and definitions  3  4 Patients older than 16 years admitted in the emergency department of our teaching hospital 5 with antithrombotic-related major haemorrhage were consecutively included between January 6 haemorrhage and patients with other major bleeding 5 6
The primary outcome was 1-month mortality. 7 8
Between subgroups comparisons were performed using student's t test for parametric data, 9
Mann-Whitney U test for non parametric data, and the chi-square test for qualitative data. 10
Crude relative risks were estimated along with 95% confidence interval. Prognostic factors for 11 death at 1-month were defined in the overall population and in the subgroups of patients with 12
intracranial haemorrhage and patients with other bleeding than intracranial haemorrhage. 13
Multivariate logistic models were run in subgroups of patients with intracranial haemorrhage 14 and of patients with other major bleeding to assess the predictors of death. Statistical analysis 15 was conducted using SAS software version 9.3 (SAS Institute Inc, Cary, NC, USA). A p 16 value of .05 was considered statistically significant. 17 18 19
Results

2
Population characteristics 3 4
In 2011 and 2012, 98,377 adult patients were admitted in our emergency department. Nine 5 hundred and thirteen patients (0.9%) with major bleeding while receiving at least one 6 antithrombotic drug were analysed, which represented 1.2 patients per day. During the study 7 period, there were no monthly variations. The mean age was 80 ± 10 years ( range : 21-103); 8 median, 82 years) with a sex ratio of 1.1. Hospitalization was required for 728 patients (79%) 9
with a mean length of stay of 8.5 ± 14.2 days, including 1.3 ± 3.9 days in intensive care units. 10 11
Demographic characteristics and indications of antithrombotics, according to the therapeutic 12 subgroups, are reported in table 1. Among 913 patients, 152 (17.2%) had a combination of 13 antithrombotic agents. The duration of prescription was unknown in 46.3% of cases. 14 Gastrointestinal bleeding and intracranial haemorrhage (ICH) represented more than 70% of 15 major haemorrhagic events (table 2) . There was a statistically significant association between 16 types of antithrombotics and types of haemorrhage (p < .0001): AP-related haemorrhages 17
were mostly ICH (n = 164, 39%) and gastrointestinal bleeding (n = 179, 42%) whereas OA-18 related haemorrhages were mostly external haemorrhages or muscular hematomas (n = 147, 19 34%), gastrointestinal bleeding (n = 140, 33%) and ICH (n = 134, 31%). 20
The mechanism of the ICH, known in 307 patients, was traumatic in 44.6% of cases, mostly a 21 fall from standing height, spontaneous in 45.6%, impossible to determine in 9.4%. In 22 traumatic ICH, there were more patients with AP than OA (60% versus 40%). Frequencies of 23 AP and OA were similar in those patients with spontaneous ICH (51.5% versus 48.5%).
25
Predictors of 1-month mortality 26 27
At 1 month, data from 903 documented medical records were analysed. In this population, 28
179 patients died at 1 month (19.8 %). Fifty-five patients died in the emergency ward. 29
Death occurred within the first 3 days of hospitalization in 81 patients. The distribution of 30 death according to the type of haemorrhagic events showed that intracranial haemorrhage was 31 responsible of the most number of death (115/179 patients, 64.2%). Among 267 patients with 32 a known ICH mechanism and a known vital status at 1 month, 1-month mortality was higher 33 in spontaneous ICH than in traumatic ICH: 45.9% (62/135) vs. 26.5% (35/132), p = 0.001. 34
Among 314 patients with ICH, 27 (8.6%) had limitation of life support; 22 patients (7.7%) out 35 of the 287 remaining patients underwent surgery: 18 out of those 22 patients were alive at one 36 month (81.8%) compared to 178 out of 265 patients who did not have surgery (67.2%), p = 37 0.15. Among 342 patients with GI bleeding, 61 had an invasive therapy (endoscopy, n = 42; 38 surgery, n = 20; embolisation, n = 3; of note 4 patients had two procedures); 59 out of those 39 61 patients were alive at one month (96.7%) compared to 249 out of 281 patients who did not 40 have invasive therapy (88.6%), p = 0.055.One-month mortality was not associated with the 41 type of antithrombotic agents (table 3) . 42
In univariate analysis, prognostic factors for 1-month mortality in case of intracranial 43 haemorrhage were age, Glasgow coma scale (GCS) score, the type of antithrombotic agents 44 (OA), time between admission and diagnosis and time between admission and biological 45 results (table 4) . OA was associated with a 1.4-fold increased risk for 1-month mortality 46 compared to AP: RR = 1.5 (95%CI, 1.1 to 2.0); relative risk for PA compared to AP was 1.2 47 (95%CI, 0.6 to 2.5). Prognostic factors for 1-month mortality after other haemorrhagic events 48
were age, mean arterial pressure at admission and type of antithrombotic agents (table 4) . PA 49 was associated with a 1.7-fold increased risk for 1-month mortality compared to AP: RR = 1.7 1 (95%CI, 0.8 to 3.3); relative risk for OA compared to AP was 0.8 (95%CI, 0.5 to 1.4). 2
Adjusting for age and GCS through multivariate logistic regression, OA remained statistically 3 associated with ICH 1-month mortality compared to AP (p = 0.0451) and PA did not reached 4 statistical significance for other haemorrhagic event 1-month mortality compared to AP (p = 5 0.57). 6
Among surviving patients at 1 month (724) With more than one patient per day admitted in our emergency ward on a two-year period, our 3 study highlighted the magnitude of major bleeding associated with antithrombotics, whatever 4 the antithrombotic drug. 5 6
The patient's median age was high (82 years old), reflecting the increasing use of 7 antithrombotic in elderly in all their indications, as previously reported [4] . Particularly, the 8 number of patients with atrial fibrillation will progressively increase in the next years. 9
Consequently, the number of major bleeding will still increase in this frail population, leading 10
to an important morbidity and mortality. Despite this increased haemorrhagic risk secondary 11
to age, the elderly still have the most important benefits of antithrombotics, even after a major 12 bleeding event [8] . In survivors, we observed that 53 % of the oral anticoagulant group and 13 61% of the antiplatelet group continued the same antithrombotic treatment 1 month after the 14 haemorrhagic event. 15 16
In our study, 152 patients were taking more than one antithrombotic drugs with various 17
combinations. Even if the combination of antithrombotics increase the haemorrhagic risk [9, 18 10] the various combination would have complicated the analysis of our study population. 19
Thus, to compare the different antithrombotic agents, we classified our patients in only three 20 therapeutic groups, considering that the haemorrhagic risk was most important with oral and 21 parenteral anticoagulants than with antiplatelet agents [1, 11] . We identified 64 patients with 22 major bleeding associated with parenteral anticoagulant, especially heparins and 23 fondaparinux. To our knowledge, this was the first report on major bleeding in an ambulatory 24 population with these antithrombotics. Usually, most data came from multicenter clinical trial 25
[13]. Our results showed that the corresponding population was different from patients of 26 others therapeutic groups, i.e. more severity, increased mortality rate in patients with mainly 27 venous thromboembolic indication. In this group, the distribution of the different 28 haemorrhagic complications was equivalent to other group of antithrombotics, as previously 29
reported [14] . 30 31
In the therapeutic management of the hemorrhagic events, there were an important number of 32 blood transfusions, with numerous haemostatic procedures (surgery, endoscopic procedure). 33
Indications of blood transfusions were left to physician appreciation. In the oral anticoagulant 34 group, reversal therapy was used in only 50.5 % of cases, despite the national guidelines [7] . 35
In ICH associated with oral anticoagulant, reversal therapy with PCC and vitamin K was 36 specially used because of the poor prognosis of this bleeding event. Nevertheless, the 37 mortality rate was not different with or without reversal therapy in case of ICH. This high mortality has been reported elsewhere [18, 19] and seemed to be dependant to the 5 mechanism of the ICH and to the antithrombotic medication. In a multicenter Italian study in 6 emergency departments, Baldi and al reported a mortality rate of 44% in post traumatic IHC 7 (41% with AP and 51% with OA), and 58% in spontaneous ICH (51% with AP and 69% with 8
OA [4] . Like others, we found that age and Glasgow coma scale will be strong prognostic 9 factors in patients with intracranial haemorrhage. In case of ICH, time between admission and 10 diagnosis and time between admission and first biological results were significantly shorter in 11 patients who died, which could be explained by a more severe condition on admission. 12
In head trauma, oral anticoagulant led to 10-fold higher incidence of intracranial 13 haemorrhagic lesions ( Our study was monocentric and in part retrospective. Computer requests were made every 1 month in a retrospective manner, which could explain a lost of some data concerning medical 2 history and antithrombotic duration. However, this design could provide an unbiased 3 observation of real life behaviour because patients' management was not influenced by the 4 knowledge of an ongoing study. Because of the heterogeneity of diagnostic codes, we listed 5 about 40 different symptoms and diseases related to haemorrhagic events. 6
We used criteria of major bleeding recommended by the French National Authority for Health 7 (Haute Autorité de Santé -HAS) [7] rather than criteria of the International Society on 8
Thrombosis and Haemostasis (ISTH) defined by Schulman et al [28] . We thought that all 9 these criteria were close to each other, which would not have modified our population. In 10 addition, we thought that the fall in haemoglobin level of 20g/L or more is a less suitable 11 criterion for an emergency recruitment. 12 13 14
Conclusion 15 16
Our study shows the magnitude of major bleeding in a very old population taking 17 antithrombotics, admitted in the emergency department of a teaching hospital. Oral 18 anticoagulants and antiplatelet drugs are equally implicated in this iatrogenic pathology. The 19 severity is attested by a high mortality (about 20%) at one month after the haemorrhagic 20 event. Intracranial haemorrhage, age and Glasgow coma scale at admission are prognostic 21
factors. In case of intracranial haemorrhage, oral anticoagulant is a predictor of death. 22
The high frequency of these events and the important mortality rate suggest a great vigilance 23 in risk benefit imbalance of antithrombotic medication for individual patients, especially for 24
elderly .  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  1  2  3  4  5  6 References 7 
